Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 37 publications
Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling.
Journal: Cancer research
Published: May 09, 2022
Onvansertib and paclitaxel combined in platinum-resistant ovarian carcinomas.
Journal: Therapeutic advances in medical oncology
Published: September 10, 2021
A novel PLK1 inhibitor onvansertib effectively sensitizes MYC-driven medulloblastoma to radiotherapy.
Journal: Neuro-oncology
Published: September 03, 2021
A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 06, 2020
Onvansertib, a polo-like kinase 1 inhibitor, inhibits prostate stromal cell growth and prostate smooth muscle contraction, which is additive to inhibition by α1-blockers.
Journal: European journal of pharmacology
Published: July 23, 2019
Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer.
Journal: PloS one
Published: December 28, 2018
EGFR Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an EGFR Tyrosine Kinase Inhibitor.
Journal: JCO precision oncology
Published: November 01, 2018
Discrepancy in risk assessment of hormone receptor positive early-stage breast cancer patients using breast cancer index and recurrence score.
Journal: Breast cancer research and treatment
Published: June 28, 2018
High-Risk Human Papillomavirus Detection in Urine Samples From a Referral Population With Cervical Biopsy-Proven High-Grade Lesions.
Journal: Journal of lower genital tract disease
Published: December 23, 2017
Urine test for EGFR analysis in patients with non-small cell lung cancer.
Journal: Journal of thoracic disease
Published: November 30, 2017
Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 04, 2017
Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 15, 2017
Last Updated: 09/26/2026